Related Experiment Video
Updated: Jan 30, 2026

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
The emerging treatment landscape of advanced non-small cell lung cancer
Panagiota Economopoulou1, Giannis Mountzios2
1Medical Oncology Department, "Attikon" University Hospital, Athens, Greece.
Abstract:
Lung cancer remains the leading cause of cancer related death worldwide. Despite broad advances in diagnostics and therapy, the five-year overall survival for patients with advanced non-small cell lung cancer (NSCLC) has not significantly changed over the past few years. Following the decoding of human cancer genome and the advent of therapies targeting driver mutations, the selection of systemic therapy changed from "one size fits all" approach to a more precise selection of biologic therapies targeting distinct genetic profiles. Molecular alterations can be targeted by specific drugs that are administered orally, have higher response rates and a better toxicity profile compared to standard chemotherapy. More recently, better understanding of the interactions between tumor cells and the immune system has led to the development of new therapeutic strategies that enhance the body's own immune response towards antitumor immunity. Robust data on these new drugs have been generated not only in the second-line setting, but also as first line therapy and in combination with standard therapies. In this review, we aim to illustrate a comprehensive up-to-date within the newest advances in the field of NSCLC, with the view to educate new practitioners and stimulate new thoughts for clinical trials.
Insights
Targeted therapies and immunotherapies are revolutionizing non-small cell lung cancer (NSCLC) treatment. These advances offer improved outcomes and better toxicity profiles for patients with advanced lung cancer.
Area of Science:
- Oncology
- Genomics
- Immunology
Background:
- Lung cancer is a leading cause of cancer death globally.
- Advanced non-small cell lung cancer (NSCLC) survival rates have seen limited improvement.
- Traditional chemotherapy is being replaced by precision medicine approaches.
Purpose of the Study:
- To provide a comprehensive review of recent advancements in NSCLC treatment.
- To highlight the shift towards targeted therapies and immunotherapies.
- To educate practitioners and stimulate future clinical trial research.
Main Methods:
- Review of current literature on NSCLC diagnostics and therapeutics.
- Analysis of data from recent clinical trials involving targeted drugs and immunotherapies.
- Synthesis of information on molecular alterations and immune system interactions.
Main Results:
- Genomic decoding has enabled targeted therapies with improved efficacy and safety.
- Immunotherapies enhancing antitumor immunity represent a significant therapeutic advance.
- New drugs show promise in first-line and combination settings for NSCLC.
Conclusions:
- Precision medicine, including targeted agents and immunotherapies, is transforming NSCLC care.
- These novel approaches offer better response rates and toxicity profiles than standard chemotherapy.
- Continued research and clinical trials are essential to further optimize NSCLC treatment strategies.
Related Concept Videos
Introduction Cardiac Emergencies
Treatment Resistant Cancers
Emerging Adulthood
Lung Capacity
Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
Extraction: Advanced Methods

